Imfinzi is the first immunotherapy for the treatment of locally-advanced, unresectable NSCLC in patients whose tumours express PD-L1 on 1% or more of tumour cells
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion, recommending a marketing authorisation of Imfinzi ( Durvalumab ) for the treatment of locally-advanced, unresectable non-small cell lung cancer ( NSCLC ) in adults whose tumours express PD-L1 on greater than or equal to 1% of tumour cells and whose disease has not progressed following Platinum-based chemotherapy and radiation therapy ( CRT ).
The recommendation is based on the progression-free survival ( PFS ) and overall survival ( OS ) primary endpoints of the phase III PACIFIC trial, and post-hoc subgroup analyses by PD-L1 expression requested by the CHMP.
Durvalumab is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
In the PACIFIC trial, Durvalumab demonstrated a statistically-significant and clinically-meaningful improvement in PFS and OS in all-comer patients.
The recommended label reflects most of the patients in the trial with a known PD-L1 status.
Stage III ( locally advanced ) NSCLC is commonly divided into three sub-categories ( IIIA, IIIB and IIIC ), defined by how much the cancer has spread locally and the possibility of surgery.
Stage III disease is different from stage IV disease, when the cancer has spread ( metastasised ) to distant organs, as stage III is currently treated with curative intent.
Stage III NSCLC represents approximately one-third of NSCLC incidence and was estimated to affect around 105,000 patients in the top-eight countries ( China, France, Germany, Italy, Japan, Spain, UK, US ) in 2017.
The majority of stage III NSCLC patients are diagnosed with unresectable tumours.
No new treatments beyond chemoradiation therapy, followed by active surveillance to monitor for progression, have been available to patients for decades.
The PACIFIC trial is a randomised, double-blinded, placebo-controlled, multi-centre trial of Durvalumab as treatment in all-comer patients ( i.e. regardless of PD-L1 status ) with unresectable, stage III NSCLC whose disease has not progressed following Platinum-based chemotherapy and radiation therapy.
The trial is being conducted in 235 centres across 26 countries involving 713 patients.
The primary endpoints of the trial are PFS and OS, and secondary endpoints include landmark PFS and OS, objective response rate ( ORR ), and duration of response ( DoR ). ( Xagena )
Source: AstraZeneca, 2018
Primary analysis of CITYSCAPE study of the anti-TIGIT antibody Tiragolumab plus Atezolizumab versus Atezolizumab as first-line treatment in patients with PD-L1-selected NSCLC
The immunomodulatory receptor TIGIT is a novel inhibitory immune checkpoint present on activated T cells and NK cells in multiple...
Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer: results from GEOMETRY mono-1 study
In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, Capmatinib ( Tabrecta ) has shown efficacy in METex14–mutated non–small cell...
Hyperprogressive disease in advanced non–small cell lung cancer patients treated with immune checkpoint inhibitors
Hyperprogressive disease ( HPD ) is a paradoxical boost in tumour growth described in a subset of cancer patients treated...
Pembrolizumab in combination with chemotherapy has improved overall survival versus chemotherapy alone as first-line treatment for patients with advanced NSCLC whose tumors do not express PD-L1
The first-line treatment with Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has demonstrated improvements in overall...
FDA has warned about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer
The FDA ( U.S. Food and Drug Administration ) has warned that Ibrance ( Palbociclib ), Kisqali ( Ribociclib ),...
The European Commission has granted marketing authorization in the European Union ( EU ) for the precision oncology treatment Vitrakvi...
Keytruda as first-line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma: two new regimens approved by European Commission
The European Commission ( EC ) has approved Keytruda , an anti-PD-1 therapy, as monotherapy or in combination with Platinum...
Ibrance: FDA has expanded approved use of metastatic breast cancer treatment to include male patients
The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...
FDA has approved Piqray, the first PI3K inhibitor for HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer
The FDA ( U.S. Food and Drug Administration ) has approved Piqray ( Alpelisib ) tablets, to be used in...
Lorviqua for treatment of adult patients with ALK-positive advanced non-small cell lung cancer, previously treated with one or more ALK tyrosine kinase inhibitors: approved in European Union
The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada...